Moderna and immatics announce strategic multi-platform collaboration to develop innovative oncology therapeutics

Collaboration combines leading technologies to develop breakthrough, mrna-enabled in vivo expressed tcer® molecules companies to leverage immatics' xpresident® target discovery platform and moderna's mrna technology for the development of novel cancer vaccines collaboration to include evaluation of immatics' investigational ima203 prame tcr-t in combination with moderna's investigational prame mrna cancer vaccine immatics to receive $120 million upfront cash payment plus research funding with the potential for additional milestone and royalty payments cambridge, ma and tuebingen, germany / accesswire / september 11, 2023 / moderna, inc. (nasdaq:mrna, "moderna") and immatics n.v. (nasdaq:imtx, "immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of t cell-redirecting cancer immunotherapies, today announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need.
MRNA Ratings Summary
MRNA Quant Ranking